To Evaluate the Safety, Tolerability and Pharmacokinetics of Oral NNZ-2591 in Healthy Volunteers
A Combined Single Dose and Multiple Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of NNZ-2591 in Healthy Volunteers
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
This study is in two stages:
Stage 1: A First-in-Human (FIH), single dose escalation study of oral NNZ-2591 in healthy volunteers to establish safety, tolerability and pharmacokinetic parameters.
Stage 2: A First-in-Human (FIH), randomised, double-blind, placebo-controlled, Multiple Ascending Dose study (MAD) in healthy volunteers to establish safety, tolerability and pharmacokinetic parameters.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
New South Wales
-
Sydney, New South Wales, Australia, 2031
- Scientia Clinical Research
-
-
Western Australia
-
Nedlands, Western Australia, Australia, 6009
- Linear Clinical Research, The Queen Elizabeth II Medical Centre
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female subjects aged 18 to 55 years, inclusive;
- Weight at screening and admission between 45 kg and 100 kg;
- Body mass index (BMI) between 18.0 and 32.0 kg/m2 inclusive;
- Healthy as determined by the Investigator based on pre-study medical history, physical examination, vital signs, complete neurological examination and 12-lead electrocardiogram (ECG);
- Negative tests for Hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (anti-HCV) and human immunodeficiency virus (HIV)-1 and HIV-2 antibody at screening;
- Clinical laboratory test results up to >1.5 x Lower Limit of Normal (LLN) or <1.5 x Upper Limit of Normal (ULN) at screening and admission and deemed not clinically significant by the Investigator;
- Negative screen for alcohol and drugs of abuse at screening and admission;
Non-smokers or ex-smokers (must have ceased smoking >3 months prior to screening visit);
If female:
- Woman with no childbearing potential by reason of surgery or at least 1year post- menopause (i.e., 12 months post last menstrual period), and menopause confirmed by follicle-stimulating hormone (FSH) testing;
- If of childbearing potential, using an effective nonhormonal method of contraception (intrauterine device; condom or occlusive cap [diaphragm or cervical or vault caps]; true abstinence; or vasectomized male partner (provided that he is the sole partner of that subject and had a vasectomy ≥30 days prior to screening) for the duration of the study and up to one month after the last investigational medicinal product (IMP) administration;
Negative serum pregnancy test at screening and negative urine pregnancy test on admission (women of childbearing potential only);
If male:
- Using an effective method of contraception (condom) if sexually active with a female partner of child-bearing potential; true abstinence; or vasectomy ≥30 days prior to screening) throughout the study and for one month after the last IMP administration.
Exclusion Criteria:
- Subjects who have a clinically relevant history as determined by the Investigator, or presence of respiratory, gastrointestinal, renal, hepatic, haematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, endocrine, connective tissue diseases or disorders;
- Fridericia's correction factor for QT (QTcF) > 450 ms for male participants and >470ms for female participants or history of QT interval prolongation.
- Have a clinically relevant surgical history, as determined by the Investigator;
- Have a history of relevant atopy or drug hypersensitivity;
- Have a history of alcoholism or drug abuse;
- Consume more than 21 standard drinks a week for males and more than 14 standard drink if female [1 standard drink is any drink containing 10g of alcohol, regardless of container size or alcohol type].
- Have a significant infection or known inflammatory process on screening or admission;
- Have acute gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea, heartburn) at the time of screening or admission;
- Have used any prescription or non-prescription medicines within 2 weeks of admission, unless in the investigator's opinion will not affect determination of safety or other study assessments. Occasional paracetamol use (up to 2g/day is permitted);
- Have received any investigational drug within 30 days prior to screening;
- Have used tobacco or nicotine products within 3 months of screening
- Have donated or received any blood or blood products within the 3 months prior to screening;
- Cannot communicate reliably with the investigator;
- Are unlikely to co-operate with the requirements of the study;
Are unwilling or unable to give written informed consent.
If female:
- Pregnancy or breast-feeding;
Woman of childbearing potential not willing to use an accepted effective contraceptive method or using hormonal contraceptives;
If male:
- Not willing to use an accepted effective method of contraception.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: NNZ-2591 Single dose Cohort 1
Single dose of oral NNZ-2591 in healthy volunteers
|
Single dose of NNZ-2591
|
|
Experimental: NNZ-2591 Single dose Cohort 2
Single dose of oral NNZ-2591 in healthy volunteers
|
Single dose of NNZ-2591
|
|
Experimental: NNZ-2591 MAD Cohort 1
Multiple Ascending Dose (MAD) of oral NNZ-2591 in healthy volunteers
|
Single dose of NNZ-2591
Comparator for double-blind MAD
|
|
Experimental: NNZ-2591 MAD Cohort 2
Multiple Ascending Dose (MAD) of oral NNZ-2591 in healthy volunteers
|
Single dose of NNZ-2591
Comparator for double-blind MAD
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Safety and Tolerability measured through Adverse Events /Serious Adverse Events
Time Frame: 25 days
|
The frequency and severity of Adverse Events in healthy volunteers administered single and repeated oral doses of NNZ-2591
|
25 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pharmacokinetic - Cmax
Time Frame: 17 days
|
Maximum observed plasma concentration (Cmax) of NNZ-2591
|
17 days
|
|
Pharmacokinetic - AUC∞
Time Frame: 17 days
|
Area under the concentration-time curve from time 0 to infinity of NNZ-2591
|
17 days
|
|
Pharmacokinetic - Tmax
Time Frame: 17 days
|
Time to Cmax of NNZ-2591
|
17 days
|
|
Pharmacokinetic - t1/2
Time Frame: 17 days
|
Terminal elimination half-life
|
17 days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: James Shaw, Neuren Pharmaceuticals
- Principal Investigator: Jasmine Williams, Linear Clinical Research
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
Other Study ID Numbers
- NEU-2591-HV-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Volunteers
-
NCT01739647CompletedHealthy Elderly Volunteers | Healthy Young Volunteers
-
NCT02922933CompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human Volunteers
-
NCT02922946CompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human Volunteers
-
NCT04753580CompletedHealthy Volunteers | Frail Volunteers
-
NCT03769389CompletedGI Glycaemic Index Healthy Volunteers | GL Glycaemic Load Healthy Volunteers
-
NCT03194139Completed
-
NCT03164109Completed
-
NCT03163173CompletedHealthy | Healthy Volunteers
-
NCT06646458CompletedHealthy Elderly | Healthy Volunteers
-
NCT03278535CompletedHealthy Volunteers | Healthy Subjects | Healthy Adults
Clinical Trials on NNZ-2591
-
NCT07281079RecruitingPhelan-McDermid Syndrome
-
NCT07593391RecruitingPhelan-McDermid Syndrome
-
NCT05879614WithdrawnPrader-Willi Syndrome
-
NCT05025332CompletedPitt Hopkins Syndrome
-
NCT05025241CompletedPhelan-McDermid Syndrome
-
NCT05011851Completed
-
NCT01420042CompletedBrain Injuries, Traumatic
-
NCT02173769CompletedPulmonary Disease, Chronic Obstructive